Adult Vaccines Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 19.97 Bn

Forecast Year, 2035

USD 50.39 Bn

CAGR, 2026 - 2035

9.70%

Report Coverage

Global

What is the Adult Vaccines Market Size?

The global adult vaccines market size was calculated at USD 19.97 billion in 2025 and is predicted to increase from USD 21.9 billion in 2026 to approximately USD 50.39 billion by 2035, expanding at a CAGR of 9.70% from 2026 to 2035.The market is driven by increasing disease burden and growing focus on preventive healthcare.

Market Highlights

• By region, North America dominated the market with a major share of 50% in 2025.
• By region, Asia Pacific is expected to grow at the fastest CAGR of 10.1% in the market during the forecast period.
• By vaccine type, the influenza vaccines segment held a dominant position in the market with a share of 30% in 2025.
• By vaccine type, the HPV vaccines segment is expected to grow at the fastest CAGR in the market between 2026 and 2035.
• By application, the routine immunization segment held the largest share of 50% in 2025.
• By application, the travel vaccines segment is expected to grow at a significant CAGR in the market during the studied years.
• By distribution channel, the hospitals & clinics segment led the global market with a share of 45% in 2025.
• By distribution channel, the pharmacies/retail pharmacies segment is expected to expand at the fastest CAGR of 8.8% in the coming years.
• By age group, the 31–50 years segment registered dominance in the global market with a share of 30% in 2025.
• By age group, the above 65 years segment is expected to grow at the fastest CAGR of 9.0% over the forecast period.

Market Overview

The adult vaccines market refers to the global industry focused on vaccines administered to individuals aged 18 years and above to prevent or reduce the severity of infectious and non-infectious diseases. It includes vaccines for influenza, pneumococcal disease, hepatitis, HPV, zoster (shingles), and other adult-targeted immunizations. The market is experiencing steady growth, driven by a combination of demographic, epidemiological, and policy-related factors.

Rising incidences of infectious diseases among adults, along with increased awareness of preventive healthcare and the long-term benefits of immunization beyond childhood, are key contributors. The global population is aging rapidly, leading to higher demand for vaccines targeting age-related conditions such as influenza, pneumococcal disease, and shingles. Additionally, government-led public health campaigns, increased funding, and expanded vaccination programs are improving vaccine access and coverage, particularly in developing countries.

How is AI Influencing the Adult Vaccines Market?

Artificial intelligence is revolutionizing the adult vaccines market by increasing the efficiency in the research, development, manufacturing, and distribution process. AI-based algorithms are utilized in the context of vaccine discovery to analyze vast amounts of biological data, identify potential antigens, predict immune responses, and optimize vaccine formulations, significantly reducing development timelines. In clinical trials, AI improves trial success by enhancing patient selection, forecasting outcomes, and enabling real-time monitoring of safety signals. Additionally, AI supports vaccine supply chain management through predictive analytics that improve inventory planning, enhance cold-chain visibility, and increase distribution efficiency.

Adult Vaccines Market Trends

• There is a strong focus on preventative healthcare, which is contributing to the high vaccination rates among adults, with the assistance of the awareness campaigns and doctors' recommendations for the use of the vaccines.
• The growing geriatric population and the rise in susceptibility to infections are increasing the demand for specific vaccines against infections, particularly influenza, shingles, and pneumococcal diseases.
  Immunizations aimed at adults are currently experiencing technological change in the development of vaccines, such as mRNA, and better adjuvants.
• The growth of government-sponsored adult immunization efforts and positive reimbursement policies is boosting the availability of vaccines and coverage in both developed and developing economies.
• The booster dose recommendations for diseases such as COVID-19, tetanus, and hepatitis are on the rise, and hence, the number of repeat vaccinations among the adult population of the global population is on the rise.

Market Scope

Segment Insights

Vaccine Type Insights

Why Did the Influenza Vaccines Segment Lead the Adult Vaccines Market?

The influenza vaccines segment led the market while holding a major share of 30% in 2025 because influenza is highly prevalent and poses a significant health risk to adults, especially the elderly and individuals with chronic conditions. These vaccines are widely included in public healthcare programs worldwide and are commonly administered to working-age adults, older populations, and high-risk groups. Strong recommendations for annual vaccination from organizations such as the CDC and WHO, along with high physician endorsement, established distribution channels, and strong public awareness, have further supported uptake. In addition, employer- and government-led vaccination initiatives aimed at reducing productivity losses and healthcare costs during influenza outbreaks have reinforced the segment's market dominance.

The HPV vaccines segment is expected to grow at the fastest CAGR in the market between 2026 and 2035. The growth of this segment is driven by the growing awareness of HPV-associated cancers in both men and women, which is greatly increasing the demand for HPV vaccination. Governments and health care systems are actively developing HPV immunization regimes to encompass even adults to the age groups of the middle of their lives. Additionally, rising focus on preventive healthcare and cancer prevention strategies is accelerating demand for HPV vaccines among adults.

Application Insights

What Made Routine Immunization the Dominant Segment in the Adult Vaccines Market?

The routine immunization segment dominated the market with the largest share of 50% in 2025. This is mainly due to strong recommendations from health authorities for vaccines against influenza, tetanus, hepatitis, pneumococcal disease, and shingles. Growing awareness of the importance of lifelong immunization has encouraged adults to follow preventive vaccination schedules more consistently. Rising healthcare costs and the burden of diseases have prompted employers, insurers, and healthcare providers to promote routine immunization as a cost-saving measure. Additionally, the increasing prevalence of chronic conditions, which heighten susceptibility to infections, further reinforces the need for regular adult vaccination.

The travel vaccines segment is expected to grow at a significant CAGR in the upcoming period due to increasing global mobility and the rising awareness of preventive healthcare. Expanding international travel for business, tourism, and education has heightened the demand for vaccines such as hepatitis, yellow fever, and typhoid among adults. Governments and travel health clinics are actively promoting pre-travel immunization, particularly in response to global health emergencies. Additionally, increasing disposable incomes, especially in emerging economies, are enabling more people to travel internationally, further supporting the growth of the segment.

Distribution Channel Insights

How Does Hospitals & Clinics Lead the Adult Vaccines Market?

The hospitals & clinics segment registered dominance in the market by holding a 45% share in 2025. This is because these facilities serve as the first point of access for preventive care, chronic disease management, and routine check-ups. These settings offer high patient trust, trained medical staff, and a wide range of vaccines, making them ideal for vaccination. Vaccines requiring medical oversight, such as those for immunocompromised adults, are primarily administered in clinics due to their complexity. Additionally, the presence of robust cold-chain infrastructure, proper storage, and integrated medical records enhances the efficiency, compliance, and overall effectiveness of vaccination programs.

The pharmacies/retail pharmacies segment is expected to grow at a CAGR of 8.8% over the forecast period. The segment growth is driven by the rising consumer demand for convenient, walk-in vaccination services. With extended working hours, minimal appointment requirements, and easy accessibility, pharmacies are particularly appealing to working adults. Regulatory support allowing pharmacists to administer vaccines has expanded service offerings, while retail chains are further boosting uptake through trained staff, digital appointment scheduling, and public awareness campaigns. Government-led health initiatives have also leveraged pharmacies to increase adult immunization coverage, helping build consumer confidence in these channels.

Age Group Insights

Why Did the 31–50 Years Segment Dominate the Adult Vaccines Market?

The 31–50 years segment dominated the market with a share of 30% in 2025, primarily due to high workforce participation and greater awareness of preventive healthcare. Individuals in this age range are more likely to receive regular vaccinations, including influenza, hepatitis, tetanus, and travel-related immunizations. Employer-sponsored vaccination programs and occupational health initiatives further support vaccine uptake in this demographic. Additionally, increased global travel, exposure to diverse lifestyles, and a stronger understanding of disease prevention have encouraged a proactive approach to immunization among this group.

The above 65 years segment is expected to expand at the fastest CAGR of 9.0% in the coming years. This is because the elderly are more vulnerable to influenza, pneumococcal disease, shingles, and respiratory infection, and this is why vaccination is very important. The immunization of the elderly is currently receiving increased attention by governments and healthcare bodies via specific programs and reimbursement aid. Better information on the benefits of vaccines among seniors and caregivers is also increasing the adoption. The increasing life expectancy and the increasing attention to healthy aging are increasing expenditure on preventive healthcare, contributing to segmental growth.

Region Insights

How Big is the North America Adult Vaccines Market Size?

The North America adult vaccines market size is estimated at USD 9.99 billion in 2025 and is projected to reach approximately USD 25.45 billion by 2035, with a 9.80% CAGR from 2026 to 2035.

What Made North America the Leading Region in the Global Adult Vaccines Market?

North America led the adult vaccines market by capturing the largest share of 50% in 2025. This leadership is driven by well-established healthcare infrastructure, high utilization of preventive care, and strong awareness about adult immunization. Well-developed immunization policies, supportive government initiatives, employer-led vaccination programs, and broad access to healthcare centers help maintain stable vaccine coverage. The region's market strength is further reinforced by leading pharmaceutical companies, continuous innovation in vaccine development, and a high prevalence of chronic diseases and aging populations that sustain demand for adult vaccines.

What is the Size of the U.S.Adult Vaccines Market?

The U.S. adult vaccines market size is calculated at USD 7.49 billion in 2025 and is expected to reach nearly USD 19.21 billion in 2035, accelerating at a strong CAGR of 9.88% between 2026 and 2035.

U.S. Market Analysis

The adult vaccines market in the U.S. is growing due to the rising awareness of preventive healthcare and the benefits of immunization beyond childhood, which is encouraging more adults to get vaccinated. The aging population and increasing prevalence of chronic diseases, such as diabetes, heart disease, and respiratory illnesses, are driving demand for vaccines like influenza, pneumococcal, and shingles vaccines. Government-backed initiatives, employer-sponsored vaccination programs, and strong public health campaigns are also boosting vaccine coverage. Additionally, well-developed healthcare infrastructure, easy access to clinics and pharmacies, and innovations in vaccine formulations and delivery are supporting the growth of the market.

Why is Asia Pacific Considered the Fastest-Growing Area in the Adult Vaccines Market?

Asia Pacific is expected to grow at the fastest CAGR of 10.1% in the market during the forecast period due to the increasing access to healthcare and the increasing awareness of adult immunization. A high population base and rapid urbanization are presenting great growth opportunities, as well as rising healthcare spending is boosting the demand for novel vaccines. Governments around the region are strengthening the immunization programs and the state health infrastructures. The increasing prevalence of infectious diseases and the growing adult population are also increasing the demand for vaccines. Moreover, improved access to vaccines, expansion of private healthcare networks, and active global collaborations that enhance vaccine development, distribution, and awareness support regional market growth.

China Market Analysis

China is a major contributor to the Asia Pacific adult vaccines market due to its large and growing population, increasing healthcare infrastructure, and rising awareness of preventive healthcare. The country is witnessing the rapid adoption of vaccines for influenza, hepatitis, pneumococcal disease, and travel-related illnesses, supported by government immunization programs, expanding private healthcare networks, and rising disposable incomes that enable greater access to adult vaccination services.

Who are the Major Players in the Global Adult Vaccines Market?

The major players in the adult vaccines market include GlaxoSmithKline plc (GSK), Sanofi S.A. , Merck & Co., Inc. , Pfizer Inc., AstraZeneca plc, Moderna, Inc. BioNTech SE Serum Institute of India Pvt. Lt, Bavarian Nordic A/S, Emergent BioSolutions Inc., Sinovac Biotech Ltd,. Johnson & Johnson Services, In,.Novavax, Inc., Takeda Pharmaceutical Company Limited, Dynavax Technologies Corporation

Segments Covered in the Report

By Vaccine Type

• Influenza Vaccines
• Pneumococcal Vaccines
• Hepatitis Vaccines
• HPV Vaccines
• Zoster/Shingles Vaccines
• Meningococcal Vaccines
• Others

By Application

• Routine Immunization
• Travel Vaccines
• Occupational/Other Immunization
• Outbreak/Response Vaccination

By Distribution Channel

• Hospitals & Clinics
• Pharmacies/ Retail Pharmacies
• Government Suppliers
• Others

By Age Group (Adult Cohorts)

• 18–30 years
• 31–50 years
• 51–65 years
• Above 65 years

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa